Form 8-K

8-K — SELECT MEDICAL HOLDINGS CORP

Accession: 0001104659-26-078332

Filed: 2026-06-26

Period: 2026-06-26

CIK: 0001320414

SIC: 8060 (SERVICES-HOSPITALS)

Item: Submission of Matters to a Vote of Security Holders

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — tm2619083d1_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (tm2619083d1_ex99-1.htm)

GRAPHIC (tm2619083d1_ex99-1img001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2619083d1_8k.htm · Sequence: 1

false

0001320414

2026-06-26

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

current

report

Pursuant to Section 13

or 15(d) of the

Securities Exchange

Act of 1934

Date of Report (Date

of earliest event reported): June 26, 2026

SELECT

MEDICAL HOLDINGS CORPORATION

(Exact name of registrant

as specified in its charter)

Delaware

001-34465

20-1764048

(State or other jurisdiction of

Incorporation)

(Commission File

Number)

(I.R.S. Employer

Identification No.)

4714 Gettysburg Road, P.O. Box 2034

Mechanicsburg, PA 17055

(Address of principal executive offices) (Zip Code)

(717) 972-1100

(Registrant’s telephone number, including

area code)

Securities registered pursuant to Section

12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share

SEM

New York Stock Exchange (NYSE)

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the

Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the

Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b)

under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c)

under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether either registrant is an emerging

growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities

Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if either registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards

provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.07 Submission of Matters to a

Vote of Security Holders

Select Medical Holdings Corporation

(the “Company” or “Select Medical”) held a special meeting of its common stockholders (the “Special Meeting”)

on June 26, 2026. A brief description of the matters voted upon at the Special Meeting and the results of the voting on such matters is

set forth below. At the Special Meeting, there were present, online or represented by proxy, 102,299,245 shares of the Company’s common

stock (the “Company Shares”), representing 82.54% of the 123,942,955 Company Shares outstanding and eligible to vote.

This constituted a quorum for all matters to be presented at the Special Meeting. The record date for the Special Meeting was May 11,

2026.

Following the approval of

the Merger Proposal (as defined below) at the Special Meeting, the Company, Parent and Merger Sub (each as defined below) anticipate the

transactions contemplated by the Merger Agreement (as defined below), including the merger, will close on or about June 30, 2026.

The number of votes cast for

and against, as well as the number of abstentions, with respect to each proposal presented at the Special Meeting were as follows:

Proposal 1: The Merger Proposal

The Merger Proposal is a proposal

to adopt that certain Agreement and Plan of Merger (the “Merger Agreement”), dated as of March 2, 2026, as may be amended

from time to time by and among the Company, Stallion Intermediate Corporation (“Parent”) and Stallion MergerSub Corporation

(“Merger Sub”). The Merger Proposal required the affirmative vote of (i) holders of Company Shares representing a majority

of the aggregate voting power of the outstanding Company Shares entitled to vote thereon (“Majority Approval”) and (ii) holders

of Company Shares representing a majority of the aggregate voting power of the outstanding Company Shares entitled to vote thereon, excluding

any Company Shares beneficially owned by Parent, Merger Sub, the Rollover Holders (as defined in the Merger Agreement) and their respective

Affiliates, “associates” or members of their respective “immediate family” (as such terms are respectively defined

in Rules 12b-2 and 16a-1 of the Exchange Act) (collectively, “Unaffiliated Stockholder Approval”).

For:

Against:

Abstain:

Majority Approval

99,005,011

1,789,017

1,505,217

Unaffiliated Stockholder Approval

81,819,453

1,789,017

1,505,217

Proposal 2: The Compensation Proposal

The Compensation Proposal

is a proposal to approve, on a non-binding, advisory basis, certain compensation that will or may become payable by the Company to its

named executive officers that is based on or otherwise relates to the merger. The Compensation Proposal required the affirmative vote

of a majority of the Company Shares present online or represented by proxy at the Special Meeting and entitled to vote thereon.

For:

Against:

Abstain:

52,322,733

48,410,193

1,566,319

Proposal 3: The Adjournment Proposal

In connection with the Special

Meeting, the Company also solicited proxies with respect to the Adjournment Proposal, or a proposal to approve adjournments of the Special

Meeting to solicit additional proxies if there are not sufficient votes at the time of the Special Meeting to approve the Merger Proposal.

The Adjournment Proposal was rendered moot in light of the approval of the Merger Proposal.

Item 7.01 Regulation FD Disclosure.

On June 26, 2026, the Company

issued a press release announcing the results of the special meeting. A copy of the press release is furnished as Exhibit 99.1 hereto

and is incorporated herein by reference.

The information in this Item

7.01 in this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed to be “filed” for purposes of

Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities

of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or

the Exchange Act, except as expressly set forth by specific reference in such filing.

Forward Looking Statements

This communication contains

forward-looking statements. Forward-looking statements use words such as “expect,” “anticipate,” “outlook,”

“intend,” “plan,” “confident,” “believe,” “will,” “should,” “would,”

“potential,” “positioning,” “proposed,” “planned,” “objective,” “likely,”

“could,” “may,” and words of similar meaning, as well as other words or expressions referencing future events,

conditions or circumstances. Statements that describe or relate to Select Medical’s plans, goals, intentions, strategies, financial

outlook, are examples of forward-looking statements. Forward-looking statements are based on our current beliefs, expectations and assumptions,

which may not prove to be accurate, and involve a number of known and unknown risks and uncertainties, many of which are out of Select

Medical’s control. Forward-looking statements are not guarantees of future performance and you should not place undue reliance on

Select Medical’s forward-looking statements. Forward-looking statements involve significant known and unknown risks and uncertainties

that may cause Select Medical’s actual results in future periods to differ materially from those projected or contemplated in the

forward-looking statements. The inclusion of such statements should not be regarded as a representation that such plans, estimates or

expectations will be achieved. There is no assurance that the proposed merger will be consummated, and there are a number of risks and

uncertainties that could cause actual outcomes and results to differ materially from the results contemplated by such forward-looking

statements, including, without limitation: (1) the inability to consummate the proposed merger within the anticipated time period, or

at all, due to any reason, including the failure to obtain any required regulatory approvals for the proposed merger or the failure to

satisfy the other conditions to the consummation of the proposed merger; (2) the risk that the proposed merger disrupts Select Medical’s

current plans and operations or diverts management’s attention from its ongoing business; (3) the effect of the announcement of

the proposed merger and results of the Special Meeting on the ability of Select Medical to retain and hire key personnel and maintain

relationships with those with whom it does business; (4) the effect of the announcement or pendency of the proposed merger on Select Medical’s

operating results and business generally; (5) the significant costs, fees and expenses related to the proposed merger; (6) the risk that

Select Medical’s stock price may decline significantly if the proposed merger is not consummated; (7) the nature, cost and outcome

of any litigation and other legal proceedings, including any such proceedings related to the proposed merger and instituted against Select

Medical and/or their respective directors, executive officers or other related persons; (8) other risks that could affect Select Medical’s

business, financial condition or results of operations, including those set forth in the Company’s most recent Annual Report on

Form 10-K and any subsequent filings; and (9) other risks to the consummation of the proposed merger. Additional information concerning

these and other factors can be found in Select Medical’s filings with the SEC, including Select Medical’s most recent annual

report on Form 10-K. Select Medical does not undertake any obligation to publicly update or revise any forward-looking statements, whether

as a result of new information, future events or otherwise.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number

Description

99.1

Press Release, dated June 26, 2026, announcing the results of the Special Meeting.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SELECT MEDICAL HOLDINGS CORPORATION

Date: June 26, 2026

By:

/s/ John F. Duggan

John F. Duggan

Executive Vice President, General Counsel and Secretary

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: tm2619083d1_ex99-1.htm · Sequence: 2

Exhibit 99.1

FOR IMMEDIATE RELEASE

4714 Gettysburg Road

Mechanicsburg, PA 17055

NYSE Symbol: SEM

Select Medical Holdings Corporation Announces

Stockholder Approval of Acquisition by Consortium Led by Robert A. Ortenzio, Martin F. Jackson, and WCAS

MECHANICSBURG, PENNSYLVANIA,

June 26, 2026 -- Select Medical Holdings Corporation (NYSE: SEM) (“Select Medical,” “we,” “us,” or

“our”) confirmed today that its previously announced Agreement and Plan of Merger (the “Merger Agreement,” and

the transaction contemplated thereby, the “Merger”) with an entity affiliated with a consortium led by Robert A. Ortenzio,

Executive Chairman, Co-Founder and Director of Select Medical, Martin F. Jackson, Senior Executive Vice President of Strategic Finance

and Operations of Select Medical, and Welsh, Carson, Anderson & Stowe (“WCAS” and, together with Mr. Ortenzio and Mr.

Jackson, the “Consortium”) was approved at a special meeting of Select Medical’s stockholders (the “Special Meeting”)

on June 26, 2026. The closing of the Merger remains subject to the terms and conditions of the Merger Agreement, as described more in

detail in the Definitive Proxy Statement on Schedule 14A (the “Definitive Proxy Statement”), filed with the U.S. Securities

and Exchange Commission (the “SEC”) on May 19, 2026. Subject to those terms and conditions, Select Medical expects that the

closing of the Merger will occur mid-2026.

Approximately 82.54% of Select

Medical’s outstanding shares were voted at the Special Meeting, and the Merger was approved by over 79.88% of Select Medical’s

outstanding shares and over 76.64% of the outstanding shares held by stockholders unaffiliated with the Consortium. Select Medical will

file the final voting results in a Current Report on Form 8-K with the SEC.

Advisors

J.P. Morgan and Wells Fargo

are serving as joint lead arrangers and joint lead bookrunners in connection with the committed debt financing of the Consortium. Goldman

Sachs is serving as the exclusive financial advisor, and Skadden, Arps, Slate, Meagher & Flom LLP is serving as legal counsel to

the Special Committee of disinterested and independent directors of the Board of Directors of the Company. Dechert LLP is serving as

legal counsel to Select Medical. Wells Fargo and J.P. Morgan are serving as financial advisors, and Cravath, Swaine & Moore LLP is

serving as legal counsel to the Consortium. Barclays is serving as financial advisor, and Ropes & Gray LLP is serving as legal counsel

to WCAS. Paul Hastings LLP is serving as legal counsel to the debt financing sources.

About Select Medical

Select Medical is one of

the largest operators of critical illness recovery hospitals, rehabilitation hospitals, and outpatient rehabilitation clinics in the

United States based on number of facilities. Select Medical’s reportable segments include the critical illness recovery hospital

segment, the rehabilitation hospital segment, and the outpatient rehabilitation segment. As of March 31, 2026, Select Medical operated

103 critical illness recovery hospitals in 28 states, 41 rehabilitation hospitals in 15 states, and 1,912 outpatient rehabilitation clinics

in 37 states and the District of Columbia. At March 31, 2026, Select Medical had operations in 38 states and the District of Columbia.

Information about Select Medical is available at www.selectmedical.com.

About WCAS

WCAS is a leading U.S. private

equity firm focused on two target industries: technology and healthcare. Since its founding in 1979, the firm’s strategy has been

to partner with outstanding management teams and build value for its investors through a combination of operational improvements, growth

initiatives, and strategic acquisitions. The firm has raised and managed funds totaling over $33 billion of committed capital. For more

information, please visit www.wcas.com.

Cautionary Statement Regarding Forward-Looking

Statements

This release contains forward-looking

statements. Forward-looking statements use words such as “expect,” “anticipate,” “outlook,” “intend,”

“plan,” “confident,” “believe,” “will,” “should,” “would,” “potential,”

“positioning,” “proposed,” “planned,” “objective,” “likely,” “could,”

“may,” and words of similar meaning, as well as other words or expressions referencing future events, conditions or circumstances.

Statements that describe or relate to Select Medical’s plans, goals, intentions, strategies, financial outlook, are examples of

forward-looking statements. Forward-looking statements are based on our current beliefs, expectations and assumptions, which may not

prove to be accurate, and involve a number of known and unknown risks and uncertainties, many of which are out of Select Medical’s

control. Forward-looking statements are not guarantees of future performance and you should not place undue reliance on Select Medical’s

forward-looking statements. Forward-looking statements involve significant known and unknown risks and uncertainties that may cause Select

Medical’s actual results in future periods to differ materially from those projected or contemplated in the forward-looking statements.

The inclusion of such statements should not be regarded as a representation that such plans, estimates or expectations will be achieved.

There is no assurance that the proposed Merger will be consummated, and there are a number of risks and uncertainties that could cause

actual outcomes and results to differ materially from the results contemplated by such forward-looking statements, including, without

limitation: (1) the inability to consummate the proposed Merger within the anticipated time period, or at all, due to any reason, including

the failure to obtain any required regulatory approvals for the proposed Merger or the failure to satisfy the other conditions to the

consummation of the proposed Merger; (2) the risk that the proposed Merger disrupts Select Medical’s current plans and operations

or diverts management’s attention from its ongoing business; (3) the effect of the announcement of the proposed Merger and results

of the Special Meeting on the ability of Select Medical to retain and hire key personnel and maintain relationships with those with whom

it does business; (4) the effect of the announcement or pendency of the proposed Merger on Select Medical’s operating results and

business generally; (5) the significant costs, fees and expenses related to the proposed Merger; (6) the risk that Select Medical’s

stock price may decline significantly if the proposed Merger is not consummated; (7) the nature, cost and outcome of any litigation and

other legal proceedings, including any such proceedings related to the proposed Merger and instituted against Select Medical and/or their

respective directors, executive officers or other related persons; (8) other risks that could affect Select Medical’s business,

financial condition or results of operations, including those set forth in the Company’s most recent Annual Report on Form 10-K

and any subsequent filings; and (9) other risks to the consummation of the proposed Merger. Additional information concerning these and

other factors can be found in Select Medical’s filings with the SEC, including Select Medical’s most recent annual report

on Form 10-K. Select Medical does not undertake any obligation to publicly update or revise any forward-looking statements, whether as

a result of new information, future events or otherwise.

Media inquiries:

Shelly Eckenroth

Senior Vice President, Chief Communications Marketing

& Branding Officer

717-920-4035

seckenroth@selectmedical.com

Investor inquiries:

Robert S. Kido

Senior Vice President and Treasurer

717-972-1100

ir@selectmedical.com

SOURCE: Select Medical Holdings Corporation

GRAPHIC

Filename: tm2619083d1_ex99-1img001.jpg · Sequence: 6

Binary file (29153 bytes)

Download tm2619083d1_ex99-1img001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Jun. 26, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jun. 26, 2026

Entity File Number

001-34465

Entity Registrant Name

SELECT

MEDICAL HOLDINGS CORPORATION

Entity Central Index Key

0001320414

Entity Tax Identification Number

20-1764048

Entity Incorporation, State or Country Code

Entity Address, Address Line One

4714 Gettysburg Road

Entity Address, Address Line Two

P.O. Box 2034

Entity Address, City or Town

Mechanicsburg

Entity Address, State or Province

Entity Address, Postal Zip Code

17055

City Area Code

717

Local Phone Number

972-1100

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value $0.001 per share

Trading Symbol

SEM

Security Exchange Name

NYSE

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration